Literature DB >> 18456554

HIV and malaria co-infection: interactions and consequences of chemotherapy.

T S Skinner-Adams1, J S McCarthy, D L Gardiner, K T Andrews.   

Abstract

The global epidemiology of HIV/AIDS and malaria overlap because a significant number of HIV-infected individuals live in regions with different levels of malaria transmission. Although the consequences of co-infection with HIV and malaria parasites are not fully understood, available evidence suggests that the infections act synergistically and together result in worse outcomes. The importance of understanding chemotherapeutic interactions during malaria and HIV co-infection is now being recognized. We know that some antimalarial drugs have weak antiretroviral effects; however, recent studies have also demonstrated that certain antiretroviral agents can inhibit malaria-parasite growth. Here, we discuss recent findings on the impact of HIV/AIDS and malaria co-infection and the possible roles of chemotherapy in improving the treatment of these diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18456554     DOI: 10.1016/j.pt.2008.03.008

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  24 in total

1.  Evaluation of a PfHRP-2 based rapid diagnostic test versus microscopy method among HIV-positive and unknown serology patients in Ouagadougou, Burkina Faso.

Authors:  Arianna Andreoli; Pier Francesco Giorgetti; Virginio Pietra; Alessia Melzani; Wetien Seni; Francesco Castelli; Jaques Simpore
Journal:  Am J Trop Med Hyg       Date:  2015-02-09       Impact factor: 2.345

2.  Antimalarial asexual stage-specific and gametocytocidal activities of HIV protease inhibitors.

Authors:  Christopher L Peatey; Katherine T Andrews; Nina Eickel; Timothy MacDonald; Alice S Butterworth; Katharine R Trenholme; Donald L Gardiner; James S McCarthy; Tina S Skinner-Adams
Journal:  Antimicrob Agents Chemother       Date:  2009-12-22       Impact factor: 5.191

3.  Severity of outcomes associated to types of HIV coinfection with TB and malaria in a setting where the three pandemics overlap.

Authors:  Jose Gaby Tshikuka Mulumba; Benjamin Atua Matindii; Albert Lukuka Kilauzi; Bibi Mengema; Jacqueline Mafuta; Gérard Eloko Eya Matangelo; Abraham Mukongo Bulaïmu-Lukeba; Itetya Lukuka Jerry
Journal:  J Community Health       Date:  2012-12

4.  Dosage of Sulfadoxine-Pyrimethamine and Risk of Low Birth Weight in a Cohort of Zambian Pregnant Women in a Low Malaria Prevalence Region.

Authors:  Marie C D Stoner; Bellington Vwalika; Marcela Smid; Andrew Kumwenda; Elizabeth Stringer; Benjamin H Chi; Jeff S A Stringer
Journal:  Am J Trop Med Hyg       Date:  2016-10-31       Impact factor: 2.345

5.  HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.

Authors:  Kimberly A Porter; Stephen R Cole; Joseph J Eron; Yu Zheng; Michael D Hughes; Shahin Lockman; Charles Poole; Tina S Skinner-Adams; Mina Hosseinipour; Doug Shaffer; Ronald D'Amico; Frederick K Sawe; Abraham Siika; Elizabeth Stringer; Judith S Currier; Tsungai Chipato; Robert Salata; James S McCarthy; Steven R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

Review 6.  The potential impact of coinfection on antimicrobial chemotherapy and drug resistance.

Authors:  Ruthie B Birger; Roger D Kouyos; C Jessica E Metcalf; Ted Cohen; Emily C Griffiths; Silvie Huijben; Michael J Mina; Victoriya Volkova; Bryan Grenfell
Journal:  Trends Microbiol       Date:  2015-05-29       Impact factor: 17.079

7.  In vitro activity of antiretroviral drugs against Plasmodium falciparum.

Authors:  Christian Nsanzabana; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

8.  Evaluation of the effect of pyrimethamine, an anti-malarial drug, on HIV-1 replication.

Authors:  Raphael M Oguariri; Joseph W Adelsberger; Michael W Baseler; Tomozumi Imamichi
Journal:  Virus Res       Date:  2010-08-26       Impact factor: 3.303

9.  Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum.

Authors:  U Lek-Uthai; R Suwanarusk; R Ruengweerayut; T S Skinner-Adams; F Nosten; D L Gardiner; P Boonma; K A Piera; K T Andrews; B Machunter; J S McCarthy; N M Anstey; R N Price; B Russell
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

10.  Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms.

Authors:  O Burk; R Piedade; L Ghebreghiorghis; J T Fait; A K Nussler; J P Gil; B Windshügel; M Schwab
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.